News for Cynata Therapeutics Limited (CYP.AX)

Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ETCompany ParticipantsLauren Nowak - Media...

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal.

PR NewswireMELBOURNE, Australia, Dec. 4, 2024 MELBOURNE, Australia, Dec. 4, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

Volatility remained the status quo as the ASX200 ended down 0.23%. The local bourse briefly touched into the green after lunch, but the mood was short-lived. The market almost immediately pared gains, sinking back into the red.

Cynata Therapeutics Ltd has published a study examining the effect of its Cymerus therapy on idiopathic pulmonary fibrosis symptoms.

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

Induced pluripotent stem cell (iPSC) market size from USD 2.1 billion in 2023 to USD 5.2 billion in 10 years. The growing incidence of cancer drive the...

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

Oct 08, 2020 / NTS GMTRoss Macdonald - Cynata Therapeutics Limited - CEO, MD Thanks, Tim, and welcome, everybody, to the session today. The development of stem

Global stem cell therapy market is segmented on the basis of therapy, and application. In terms of therapy, the market is segmented into autologous, and...

Visiongain has published a new report entitled Stem Cell Technologies and Applications Market Report 2023-2033: Forecasts by Type (Allogeneic Stem Cell...

Increase in the prevalence of chronic diseases, advances in stem cell research, and growth in investment in regenerative medicine are prominent factors...

The ASX200 closed the 2023 financial year marginally higher, ahead of significant Labor Government changes coming into effect from tomorrow.

The S&P ASX 200 gained 1.85% in April 2023, extending its YTD gain to 5.38% with mid and small caps outperforming their blue-chip peers.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

On Stockhead today, There's 14 lithium plays who now call a US mega-factory neighbour. It's Part 1 of a new Nearology series by Emma Davies.

The ASX has ended the week up 2.25%, thanks to some pre-Easter magic from the Goldies, starring Western Mines' +166.7% belter. Happy Easter!